17:12 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

ASN-002: Interim Ph I/IIa data

Interim data from 9 patients with nodular BCC in an open-label, Australian Phase I/IIa trial showed that once-weekly intratumoral ASN-002 for 3 weeks led to an overall response rate (ORR) of 100%, comprising 67% complete...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

TG1042: Phase I/II started

Ascend began an open-label, Australian Phase I/II trial to evaluate weekly intratumoral injections of ASN-002 in up to 36 patients prior to surgical tumor excision. Patients will receive ASN-002 for 3 weeks or for 7...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Ascend Biopharmaceuticals, Transgene deal

Transgene granted Ascend rights to develop and commercialize TG1042 ( ASN-002 ) to treat basal cell carcinoma, bladder cancer and an additional indication to be selected by Ascend. Transgene retains rights to other potential indications....